加速大分割放化疗后立体定向消融放疗加量治疗局部晚期不可切除非小细胞肺癌:一项非随机对照试验
这项早期、单中心、剂量递增非随机对照试验纳入28例II期(不可手术或拒绝手术)或III期非小细胞肺癌患者,评估大分割同步放化疗后自适应立体定向消融放疗加量的最大耐受剂量。方案为4 Gy×10次后加量25 Gy(低剂量)、30 Gy(中剂量)或35 Gy(高剂量),同步每周卡铂/紫杉醇。未超过方案规定的最大耐受剂量,高剂量组发生2例死亡;中剂量组未观察到3级毒性。
要点
- 方案为4 Gy×10次后自适应SABR加量25/30/35 Gy,同步每周卡铂/紫杉醇。
- 非血液学急性≥3级毒性发生率为11%,晚期(>90天)≥3级毒性为7%。
- 中剂量加量组未观察到3级毒性;高剂量组发生2例死亡。
核心结论
- 同步放化疗后自适应SABR加量至70 Gy/15次并同步化疗,对局部晚期不可切除非小细胞肺癌是安全有效的方案。
- 该早期剂量递增试验未超过方案规定的最大耐受剂量。
研究设计与样本
- 早期、单中心、放疗剂量递增非随机对照试验,同步化疗。
- 纳入临床II期(不可手术或患者拒绝手术)或III期非小细胞肺癌患者(AJCC分期手册第7版)。
- 2011年5月至2018年5月入组治疗,中位随访18.2个月;数据分析于2023年1月至9月进行。
- 共28例患者,中位年龄70岁(范围51-88),男性16例(57%),III期24例(86%);低剂量组10例、中剂量组9例、高剂量组9例。
- 若加量队列90天随访内剂量限制性毒性(任何≥3级肺、胃肠或心脏毒性,或任何非血液学≥4级毒性)发生率低于33%,则进入更高加量剂量。
主要发现
- 非血液学急性≥3级毒性发生率为11%,晚期(>90天)≥3级毒性发生率为7%。
- 中剂量加量组未观察到3级毒性;高剂量组发生2例死亡。
- 2年局部控制率:低剂量组74.1%、中剂量组85.7%、高剂量组100.0%。
- 2年总生存率:低剂量组30.0%、中剂量组76.2%、高剂量组55.6%。
关键数值与推荐
- 干预方案:所有患者先接受4 Gy×10次,后针对残留代谢活跃病灶行自适应SABR加量,低剂量为25 Gy(5 Gy×5次)、中剂量为30 Gy(6 Gy×5次)、高剂量为35 Gy(7 Gy×5次),同步每周卡铂/紫杉醇。
- 剂量递增规则:加量队列90天随访内剂量限制性毒性发生率低于33%方可进入更高剂量。
- 主要结局为确定最大耐受剂量;方案规定的最大耐受剂量未被超过。
临床怎么用
- 作者结论认为同步放化疗后自适应SABR加量至70 Gy/15次并同步化疗是安全有效的方案。
- 中剂量加量组未观察到3级毒性,高剂量组发生2例死亡。
- 原文未据此给出常规临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non-small cell lung cancer (NSCLC). OBJECTIVE: To determine the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost. DESIGN, SETTING, AND PARTICIPANTS: This was an early-phase, single-institution, radiation dose-escalation nonrandomized controlled trial with concurrent chemotherapy among patients with clinical stage II (inoperable/patient refusal of surgery) or III NSCLC (American Joint Committee on Cancer Staging Manual, seventh edition). Patients were enrolled and treated from May 2011 to May 2018, with a median patient follow-up of 18.2 months. Patients advanced to a higher SABR boost dose if dose-limiting toxic effects (any grade 3 or higher pulmonary, gastrointestinal, or cardiac toxic effects, or any nonhematologic grade 4 or higher toxic effects) occurred in fewer than 33% of the boost cohort within 90 days of follow-up. The current analyses were conducted from January to September 2023. INTERVENTION: All patients first received 4 Gy × 10 fractions followed by an adaptive SABR boost to residual metabolically active disease, consisting of an additional 25 Gy (low, 5 Gy × 5 fractions), 30 Gy (intermediate, 6 Gy × 5 fractions), or 35 Gy (high, 7 Gy × 5 fractions) with concurrent weekly carboplatin/paclitaxel. MAIN OUTCOME AND MEASURE: The primary outcome was to determine the MTD. RESULTS: Data from 28 patients (median [range] age, 70 [51-88] years; 16 [57%] male; 24 [86%] with stage III disease) enrolled across the low- (n = 10), intermediate- (n = 9), and high- (n = 9) dose cohorts were evaluated. The protocol-specified MTD was not exceeded. The incidences of nonhematologic acute and late (>90 days) grade 3 or higher toxic effects were 11% and 7%, respectively. No grade 3 toxic effects were observed in the intermediate-dose boost cohort. Two deaths occurred in the high-dose cohort. Two-year local control was 74.1%, 85.7%, and 100.0% for the low-, intermediate-, and high-dose cohorts, respectively. Two-year overall survival was 30.0%, 76.2%, and 55.6% for the low-, intermediate-, and high-dose cohorts, respectively. CONCLUSIONS AND RELEVANCE: This early-phase, dose-escalation nonrandomized controlled trial showed that concurrent chemoradiation with an adaptive SABR boost to 70 Gy in 15 fractions with concurrent chemotherapy is a safe and effective regimen for patients with locally advanced, unresectable NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01345851.
引用
- Wu TC, Luterstein E, Neilsen BK, et al. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 38206614. doi:10.1001/jamaoncol.2023.6033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。